uniQure N.V. (QURE) Shares Up 9.6%
uniQure N.V. (NASDAQ:QURE) shot up 9.6% during trading on Friday . The company traded as high as $16.54 and last traded at $15.94. 826,066 shares changed hands during mid-day trading, a decline of 54% from the average session volume of 1,792,829 shares. The stock had previously closed at $14.54.
A number of research firms have commented on QURE. ValuEngine upgraded shares of uniQure N.V. from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Zacks Investment Research cut shares of uniQure N.V. from a “hold” rating to a “sell” rating in a report on Wednesday, October 18th. Leerink Swann raised their price target on shares of uniQure N.V. from $17.00 to $19.00 and gave the stock an “outperform” rating in a report on Friday, October 20th. Finally, Chardan Capital set a $13.00 price target on shares of uniQure N.V. and gave the stock a “buy” rating in a report on Sunday, July 23rd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $15.50.
The company has a debt-to-equity ratio of 0.73, a current ratio of 3.64 and a quick ratio of 4.82.
uniQure N.V. (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.05). uniQure N.V. had a negative net margin of 338.39% and a negative return on equity of 170.28%. The firm had revenue of $4.94 million for the quarter, compared to the consensus estimate of $2.92 million. equities research analysts anticipate that uniQure N.V. will post -3.06 earnings per share for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC raised its position in uniQure N.V. by 27.5% in the first quarter. FMR LLC now owns 1,498,463 shares of the biotechnology company’s stock worth $8,661,000 after acquiring an additional 323,345 shares during the period. Renaissance Technologies LLC raised its position in uniQure N.V. by 48.8% in the first quarter. Renaissance Technologies LLC now owns 374,000 shares of the biotechnology company’s stock worth $2,162,000 after acquiring an additional 122,700 shares during the period. Paloma Partners Management Co raised its position in uniQure N.V. by 717.7% in the first quarter. Paloma Partners Management Co now owns 85,000 shares of the biotechnology company’s stock worth $491,000 after acquiring an additional 74,605 shares during the period. Morgan Stanley raised its position in uniQure N.V. by 14.9% in the first quarter. Morgan Stanley now owns 565,760 shares of the biotechnology company’s stock worth $3,271,000 after acquiring an additional 73,418 shares during the period. Finally, Mangrove Partners bought a new stake in uniQure N.V. in the second quarter worth about $247,000. 29.96% of the stock is currently owned by institutional investors.
About uniQure N.V.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.